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Abstract
Although the incidence of metastases to the pancreas from various primaries is very low, 
these lesions are usually being described as part of the systemic recurrence of differ-
ent malignancies, in certain cases isolated pancreatic metastases might be encountered. 
When it comes to the malignancies, which might lead to the apparition of pancreatic 
metastases, the most common origins have been reported to be renal cell carcinoma, 
colon cancer, ovarian cancer and melanomas. In certain cases, patients with pancreatic 
metastases might be submitted to surgery with curative intent. However, it should not 
be omitted that pancreatic resections can be associated with higher rates of perioperative 
morbidity; therefore, a precise selection of the cases that are considered suitable for such 
procedures is mandatory. It seems that the best results in regard with long-term survival 
are expected in cases with isolated pancreatic metastases as well as in cases with lim-
ited extrapancreatic lesions, amenable to complete cytoreductive surgery. This chapter 
reviews the most important studies conducted on the theme of pancreatic resections for 
metastatic disease from various primaries.
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1. Introduction
Pancreatic metastases from other primaries are rare eventualities, the reported incidence being 
less than 2% from all pancreatic lesions [1, 2]. When it comes to the most frequent tumors that 
might induce the apparition of pancreatic metastases, they consist of renal cell carcinomas, 
melanomas, breast, lung and gynecologic primaries [3]. Most times these patients are asymp-
tomatic and are detected during the follow-up examinations with pancreatic lesions with 
various localizations. When symptomatic, the most commonly reported symptoms and signs 
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consist of vomiting, abdominal pain, jaundice, upper digestive hemorrhage or weight loss, 
the apparition of such symptoms being usually associated with poor prognostic.
Once the diagnostic of malignant tumor of the pancreas is established, most of the times it 
is very difficult to distinguish between primary malignant lesions of the pancreas and meta-
static ones [4]. However, patients presenting metastatic disease are usually associated with 
better outcomes when compared to pancreatic primary tumors [5].
2. Imagistic studies for metastatic pancreatic lesions diagnostic
When it comes to the most efficient imagistic study in order to determine the existence of such 
lesions, computed tomography seems to play an important role, most commonly such lesions 
being diagnosed as singular, multinodular lesions or as a diffuse infiltration with hypervas-
cular aspect [1]. However, in up to 10% of cases, metastatic lesions of the pancreas might not 
be seen at standard computed tomography (CT), a positron emission tomography/computed 
tomography (PET-CT) is being needed. In this case, a diffuse uptake revealed by PET-CT 
studies might be associated with benign conditions (such as Graves’ disease or autoimmune 
thyroiditis), while focal uptake is rather significant for the presence of a malignant lesion. In 
such eventualities, a percutaneous biopsy is recommended in order to have a positive diag-
nostic of malignancy [6].
3. Therapeutic strategies in pancreatic metastases from various 
primaries
Unfortunately, pancreatic metastases usually develop as part of the systemic recurrence and 
are associated with other disseminated lesions; therefore, the patient will become a candidate 
for palliative oncological treatment, in order, to alleviate the symptoms. In certain cases, the 
pancreatic lesions will develop as oligometastatic disease and by this way, the patient will 
become the perfect candidate for surgical treatment with curative intent. In such cases, an 
important benefit in terms of survival might be obtained. However, even in cases presenting 
metastatic lesions, surgery has been lately implemented as standard of care due to the high 
morbidity rates of this kind of surgical procedures. For a long period of time, it has been 
considered that performing a gesture of pancreatic surgery in such cases is associated with 
unacceptable rate of postoperative complications including the risk of pancreatic leaks or 
acute pancreatitis. In the last decades, improvement in hepatobiliopancreatic techniques in 
association with the improvement of the postoperative care lead to a successful association 
of such resections as part of cytoreductive surgery for various primaries [7–10]. However, the 
prognostic in such cases is strongly related to the origin of the pancreatic lesion.
An interesting study conducted on the subject of pancreatic resection for metastatic disease 
was published by Sweeney et al. in 2009. The study had as departure point a case series of three 
patients with pancreatic metastases from various primaries submitted to different therapeutic 
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strategies; the first reported case was the one of a 51-year-old patient known with lobular breast 
cancer, 5 year earlier treated with lumpectomy, axillary node dissection and adjuvant hormonal 
therapy and renal cell cancer, submitted to left nephrectomy and adjuvant therapy consisting of 
interferon and thalidomide. The patient was further diagnosed with pulmonary metastases and 
was submitted to atypical lung resection and with an isolated pancreatic lesion measuring 4 × 
3.1 cm at the level of the distal pancreatic tail. The pancreatic lesion was successfully resected, 
the histopathological studies confirming the metastatic origin from the renal cell carcinoma. 
However, the patient was diagnosed with disseminated liver metastases and died of disease 20 
months after pancreatic surgery. The second case was the one of a 56-year-old man submitted 
to surgery 4 years earlier, a left pneumonectomy being performed at that moment. Four years 
later, he was diagnosed with an isolated lesion in the pancreatic neck, the biopsy demonstrating 
the metastatic origin of the lesion. He was submitted to an exploratory laparoscopy but due to 
the local invasion of the hepatic artery, resection was not feasible. In consequence, the patient 
was submitted to palliative chemotherapy and remained alive 3 years after the diagnostic of 
pancreatic metastases. The third case had been previously diagnosed with breast cancer for 
which she had been submitted to radical mastectomy followed by six cycles of chemotherapy; 5 
years later, she was diagnosed with a pancreatic tumor at the junction between head and body 
of the pancreas, so she was submitted to a biopsy which confirmed the metastatic character 
of the lesion. Therefore, she was successfully submitted to surgery, an oncologic resection of 
the pancreatic metastasis being performed. However, the surgical procedure was followed by 
adjuvant chemotherapy with good long-term outcomes [11].
The authors went further and reviewed the literature regarding pancreatic metastases of vari-
ous origins published until that moment. They reported a total number of 220 patients with 
this pathology with a median age of 59.2 years. Among cases which reported the symptom-
atology at the time of presentation, the authors underlined that up to 27.6% of cases were 
asymptomatic, among symptomatic cases the most commonly reported signs and symptoms 
are abdominal pain, upper digestive bleeding, weight loss and pancreatitis. When it comes to 
their localization, the most common pancreatic sites of metastases included pancreatic head 
(in 41.8% of cases) followed by body and tail (in 34.9% of cases), periampullary region (in 
8.9% of cases) and uncinate process (in 1.1% of cases); when reported, the tumor size ranged 
between 1 and 11.5 cm, the average size being of 3.9 ± 2.1 cm. As the originating tumors had 
leaded to the apparition of pancreatic metastases, the most common primary tumor was the 
kidney (in 70.5% of cases) followed by the colorectal tumors (in 6.5% of cases), melanomas 
(in 2.7% of cases) and malignant fibrous histiocytomas (in 1.8% of cases). Among the 220 
patients initially introduced in this study, surgery was performed in only 177 cases, the other 
43 patients being diagnosed with unresectable lesions. The most commonly performed surgi-
cal procedures consisted of distal pancreatectomies in 25.9% of cases and pancreatoduodenec-
tomy in 49.7% of cases, while total pancreatectomy was needed in 18.6% of cases submitted to 
surgery. When it comes to the short-term outcomes, the authors underlined that the reported 
incidence of complications was similar to the one reported in patients submitted to pancreatic 
resections for pancreatic primaries and consisted most often of pancreatic fistulas (in 6.5% of 
cases). As for the long-term outcomes, the authors calculated the median survival as well as 
the 2 year and 5 year survival rates only for pancreatic metastases from renal cell carcinoma 
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(this subtype being the most frequently reported in the present study); therefore, among 177 
patients submitted to surgery for pancreatic metastases from renal cell cancer, the median 
survival was 70 months, while the 2 year and 5 year overall survival rates were of 78 and 65%, 
respectively. These data suggest the potential benefit of pancreatic resections for metastatic 
lesions; it seems that the short-term outcomes are not significantly influenced by the meta-
static character of the lesion, while the long-term outcomes seem to reveal significant long-
term survival especially in oligometastatic lesions from renal primaries [11].
In a study conducted by Reddy et al. on 49 patients with metastatic pancreatic lesions, the main 
included primaries were renal cell carcinoma (in 21 cases), gallbladder cancer (in 6 cases), pul-
monary cancer (in 4 cases), ovarian cancer (in 4 cases), sarcomas (in 4 cases), melanomas (in 3 
cases), colorectal cancer (in 2 cases), breast cancer (in 1 case), hepatocellular carcinomas (in 1 
case), seminomas (in 1 case), Langerhans cell histiocytosis (in 1 case) and nonpancreatic endo-
crine cancers (in one case). The study was conducted for a 38 year time period and reviewed 
data from 3830 patients submitted to pancreatic surgery; among these cases, the metastatic 
origin of the tumor was demonstrated in 1.6% of cases. The median age at the time of resection 
of pancreatic lesions was 60 years, while the most commonly encountered symptoms were 
abdominal pain (in 48% of cases), followed by jaundice (in 31% of cases). When it comes to the 
most commonly performed surgical procedures, they consisted of pancreatoduodenectomy in 
31 cases, distal pancreatectomies in 14 cases and total pancreatectomy in 4 cases; among the 
14 cases submitted to distal pancreatic resections, splenectomy was associated in 13 patients. 
When it comes to the short-term outcomes, the reported morbidity rates were 52% after pan-
creaticoduodenectomy, 46% after distal pancreatectomy and 25% after total pancreatectomy; 
however, the overall mortality rate was 0. The most often reported complications were wound 
infections, followed by delayed gastric emptying or pulmonary complications. When it comes 
to the histopathological findings, the most often reported lymph node metastases originated 
from renal cell carcinomas, gallbladder carcinomas, lung, colorectal carcinomas, melanomas, 
seminomas, sarcomas and nonpancreatic endocrine tumors, while perineural and vascular 
invasion were reported in gallbladder, lung, renal cell cancers and melanomas. As for the long-
term outcomes, the authors reported a median overall survival rate after pancreatic resection 
of 3.7 years. Among long-term survivors (defined as a longer than 10 year survival after pan-
creatic resection), the most commonly reported origins were renal cell carcinomas, followed by 
Langerhans histiocytosis and seminomas. When performing an univariate analysis, the most 
important prognostic factors affecting the long-term survival were represented by the pres-
ence of perineural invasion and vascular invasion; surprisingly, the diameter of the metastatic 
tumor or lymph node metastases did not significantly influence survival. Moreover, patients 
who experienced any type of surgical complication as well as male patients trended to report 
a poorer outcome. When it comes to the influence of the cancer type on the overall prognostic, 
a significant influence was reported. The poorest outcomes were reported in patients submit-
ted to surgery for pancreatic metastases originating from melanomas, followed by cases with 
breast cancer. No patient diagnosed with pancreatic metastases from colorectal, lung cancer or 
sarcoma did experience an overall survival longer than 5 years. The best outcome was reported 
by the patient diagnosed with metastatic Langerhans cell histiocytosis and by the patient diag-
nosed with seminoma, both cases being alive more than 11 years after pancreatic surgery. 
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Another interesting conclusion of the study was the one regarding the time of diagnostic of the 
pancreatic lesions; in three cases pancreatic resection was performed synchronously with the 
resection of the primary tumor, the origin of the pancreatic metastases being represented by 
renal cell carcinoma, gallbladder cancer and ovarian cancer. In the remaining cases, pancreatic 
resection was performed for metachronous lesions; however, there was no difference in terms 
of survival between the two groups [12].
4. Pancreatic metastases from renal cell carcinoma
Renal cell carcinomas represent almost 2% of all malignant tumors in adults, being the third 
most common genitourinary tract cancer [13]. Although renal cell carcinoma is associated with 
an overall good prognostic, with 5-year survival rate of up to 95%, patients presenting distant 
metastases report a significant poorer outcome, with 5-year survival rates lower than 10%.
Pancreatic metastases with renal cell carcinoma origin can be diagnosed at the time of the diag-
nostic of the primary tumor (as synchronous lesions) or after a disease free interval (as meta-
chronous lesions). In the second case, it seems that the prognostic is significantly influenced 
by the disease free survival interval, a longer period of time between the initial diagnostic and 
the diagnostic of metastatic lesions being associated with a lower biological aggressivity and 
better chances of long-term survival [14, 15]. However, it should not be omitted that pancreatic 
metastases from renal cell carcinoma can occur even at 10–32 years from the diagnostic of the 
primary tumor, so that differential diagnosis should be kept in mind any moment in which 
a patient known with previous history of renal cell carcinoma is diagnosed with a metachro-
nous pancreatic tumor [16].
Patients with pancreatic metastases from renal cell carcinomas can remain asymptomatic for a 
long period of time or can develop signs and symptoms such as weight loss, abdominal pain, 
jaundice or even pancreatitis due to the Wirsung duct obstruction caused by tumor growth; 
in certain cases lesions located in the pancreatic head will lead to the apparition of upper 
gastrointestinal bleeding [17, 18].
Once a pancreatic metastasis with renal cell carcinoma origin is suspected at the imagistic 
studies, a fine needle biopsy might be needed in order to confirm the origin of the lesion and 
to decide which should be the therapeutic protocol. However, pancreatic metastases from 
renal cell carcinoma are the most common situation in which pancreatic resection for meta-
static disease has been proposed.
When it comes to the most important prognostic factors after pancreatic resections for pan-
creatic metastases with renal cell carcinomas, it seems that the disease free survival plays a 
central role; patients diagnosed with pancreatic metastases with a disease free survival longer 
than 2 years seem to have an improved outcome. Other factors which seem to influence the 
long-term outcomes are represented by the diameter of the tumor (tumors larger than 5 cm 
being associated with poorer outcomes), stage at the initial diagnostic and the tumoral degree 
of differentiation [19, 20].
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The largest series of cases submitted to pancreatic resections for metastatic renal cell carcino-
mas was conducted by Schwarz et al. and was published in 2014 in Annals of Surgical Oncology 
[21]. The study was conducted between May 1987 and June 2003 in 12 Franco-Belgian surgical 
centers and involved 62 patients submitted to surgery for pancreatic metastases from renal 
cell carcinomas. The median age at diagnostic was 54 years (range 31–75 years) while the most 
common reported symptoms were abdominal pain (in 24% of cases), anemia and gastrointesti-
nal bleeding (in 13% of cases) and jaundice (in 10% of cases). The mean interval from the diag-
nostic of the primary tumor to the diagnostic of the pancreatic lesion was 9.8 years (range 0–25 
years—two patients presenting with synchronous pancreatic lesions). When it comes to the 
most commonly performed surgical procedures, they consisted of pancreatoduodenectomy in 
31% of cases, distal pancreatectomies in 40% of cases, total pancreatectomies in 23% of cases 
and enucleation in 6% of cases. In order to achieve negative resection margins, in six cases 
major vascular resections with reconstruction were performed, while en bloc visceral resec-
tions were needed in other four cases (consisting of colonic resections in three cases and omen-
tectomy in one case); in other six patients the presence of other distant metastases imposed 
performing other visceral resections such as liver resection in three cases, contralateral adrenal-
ectomy in three cases and contralateral nephrectomy in other two cases. The histopathological 
studies confirmed an unique pancreatic lesion in 39 cases, while in the other 23 cases, 2 or more 
metastatic lesions were described. Moreover lymph node involvement was reported in 27% of 
cases submitted to lymph node dissection. During the early postoperative period, the authors 
reported an overall mortality rate of 6.4%; after a median follow-up of 91 months, 32 patients 
were dead of disease, 11 cases died of other non-malignant causes and 15 patients were still 
alive (5 cases being alive with disease while the remaining 10 cases were alive with no signs 
of recurrent lesions). The authors reported a 3 year, a 5 and a 10 year survival rate of 72, 63 
and 32%, respectively. Among the 37 patients who experienced recurrences, 9 cases presented 
pancreatic relapse, the median time to recurrence being of 44 months. Pancreatic relapsed pre-
sented as isolated metastases in five cases and as part of systemic relapse—in association with 
lung and liver metastases in other four patients; therefore four cases were submitted to pancre-
atic re-resection, the median survival time after re-resection being of 52.6 months (significantly 
higher compared to the one reported after conservative therapy—11.2 months, p = 0.019). 
When it comes to the most important prognostic factors influencing survival, it seems that the 
presence of extrapancreatic disease as well as the presence of lymph node metastases signifi-
cantly decreased survival. Surprisingly, the study failed to demonstrate a significant influence 
of the disease free survival interval on the overall survival rate, this fact being explained by the 
authors by the limited number of patients introduced in the current study [21].
In a similar study conducted by Ruckert et al. and published in 2016 in the International Journal 
of Surgery, the authors reviewed data from 40 patients submitted to surgery for pancreatic 
metastases from renal cell carcinomas in 2 German centers between January 1993 and October 
2014. These cases were submitted to surgery for pancreatic disease after a median period of 
125.4 months, the most commonly performed surgical procedures consisting of pancreato-
duodenectomy (in 37.5% of cases), total pancreatectomies (in 22.5% of cases), distal pancre-
atectomies (in 30% of cases), segmental resections (in 7.5 cases) and papillary resections (in 
2.5% of cases). The most commonly encountered complication was pancreatic leak and it was 
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reported in 12 cases while the postoperative overall mortality was 7.5%. When it comes to the 
long-term outcomes, the authors reported a mean overall survival of 147.9 months; however, 
none of the studied factors (including body mass index, sex, time of resection, synchronous/
metachronous lesions, symptomatic/asymptomatic lesions, resection status, existence of other 
extrapancreatic lesions, tumor dimension or lymph node status) did not significantly influ-
enced survival. This fact was explained by the authors by the relative small number of cases 
introduced in the current study [22]. Another important aspect pointed out of these authors 
is the one regarding the lymph node status: among the 21 patients who benefited from lymph 
node resection 5 patients were diagnosed with lymph node metastases; therefore the authors 
underlined the necessity of association of lymph node dissection in such cases [22].
The outcomes after pancreatic resection for pancreatic metastases with renal cell origin are 
shown in Table 1.
Name, year of 
the study
Period 
of the 
study
No. of 
patients
Disease 
free 
interval
Type of pancreatic 
resection
Early postoperative 
outcomes
Long-term 
outcomes
Schwarz, 2014 
[21]
1987–
2003
27 patients 9.8 years PD: 19 cases
DP: 25 cases
TP: 14 cases
Enucleation: 4 cases
Postoperative 
mortality: 4 cases
Overall survival 
after pancreatic 
resections: 52.6 
months
Ruckert, 2016 
[22]
1993–
2014
40 patients 125.4 
months
PD: 15 cases
DP: 12 cases
Enucleation: 3 cases
Broad papillary 
resection: 1 case
Postoperative 
mortality: 3 cases
Overall survival 
after pancreatic 
resections: 147.9 
months
Markinez, 
2013 [23]
2000–
2011
8 patients 12.42 
years
TP: 6 cases
DP: 1 case
Atypical resection: 1 case
Postoperative 
mortality: 1 case
Survival 
between 6 
months and 95 
months
Benhaim, 
2015 [24]
1997–
2012
20 patients 130 ± 59 
months
PD: 6 cases
DP: 5 cases
TP: 3 cases
Metastasectomy: 6 cases
Postoperative 
mortality: 1 case
Overall survival 
rate at 4 years: 
72%
Zerbi, 2008 
[25]
1998–
2006
23 patients 8 years PD: 4 cases
DP: 11 cases
TP: 2 cases
Metastasectomy: 5 cases
MP: 1 case
Postoperative 
mortality: 0
Overall survival 
after pancreatic 
resections: 44 
months
Yuasa, 2015 
[26]
1999–
2013
15 patients 13.4 
years
TP: 2 cases
Metastasectomy: 13 cases
Postoperative 
mortality: 0
Overall survival 
after pancreatic 
resections: not 
reached at 3.5 
year follow-up
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5. Pancreatic metastases from colorectal cancer
Colorectal cancer represents one of the most common reported malignancies worldwide, 
being the third cause of death following breast and lung cancer and the second cause of death 
among non-smokers [28]. When it comes to the most common patterns of spread in colorectal 
cancers, they are represented by the peritoneal, lymphatic and hematogenous spread; the 
hematogenous route is usually related to the apparition of parenchymatous lesions located 
in liver, lung or brain. In certain cases, pancreatic metastases from colorectal malignancies 
can occur, the estimated incidence being of 2%; these types of lesions are usually associated 
with peritoneal carcinomatosis and less often as single lesions [29]. When it comes to the most 
appropriate imagistic study in order to confirm the presence of such lesions, CT has been 
proposed, followed by PET-CT (in cases in which although the clinical symptoms are highly 
suggestive for a pancreatic lesion but standard CT failed to diagnose it). It has been reported 
that PET-CT is a highly sensitive method of diagnostic in such cases (with an estimated sen-
sitivity of 90–95%) while the specificity ranges between 65 and 85%; therefore performing a 
PET-CT in such cases seems to be responsible for the change of the therapeutic approach in 
up to half per cent of cases [6].
Isolated pancreatic metastases from colorectal cancer suitable for resections are scarce eventu-
alities, only few cases being reported so far. Therefore is difficult to establish whether surgical 
resections of such lesions is superior to the conservative treatment such chemotherapy, due to 
the small number of cases submitted to surgery. However, it seems that surgery is especially 
useful in patients with symptomatic lesions, a satisfactory symptom relief being reported [10].
6. Pancreatic metastases from melanomas
Pancreatic metastases from melanomas are rare situations, only few such cases being pre-
sented so far; moreover, most often the cases are presented as case reports or small case series 
involving less than 10 cases, a standard therapeutic protocol being hard to be established. 
Up to half of patients presenting with pancreatic metastases from melanomas present in fact 
disseminated metastatic lesions in the context of the systemic recurrence, being associated 
Name, year of 
the study
Period 
of the 
study
No. of 
patients
Disease 
free 
interval
Type of pancreatic 
resection
Early postoperative 
outcomes
Long-term 
outcomes
Sohn, 2001 
[27]
1989–
1999
10 patients 9.8 years PD: 7 cases
DP: 2 cases
TP: 1 cases
Postoperative 
mortality: 0
Overall survival 
after pancreatic 
resections at 5 
year follow-up: 
75%
Abbreviations: DP, distal pancreatectomy; PD, pancreatoduodenectomy; TP, total pancreatectomy; MP, middle 
pancreatectomy.
Table 1. Outcomes after pancreatic resections for pancreatic metastases from renal cell carcinomas.
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with an extremely poor prognostic. Less than 2% of patients with pancreatic metastases from 
melanomas will be diagnosed with oligometastatic disease, most often the primary tumor 
being an ocular melanoma [30, 31].
As for the long-term outcomes, patients presenting pancreatic metastases originating from mela-
nomas with various locations seem to have a poorer prognostic when compared to other prima-
ries due to the aggressive biological behavior of melanomas [19]. However, compared to patients 
treated in a conservative manner, it seems that patients submitted to surgery might benefit from 
a better outcome especially in cases in which complete resection of the pancreatic lesion is fea-
sible [32, 33]. When it comes to the most important prognostic factors which might influence the 
long-term outcomes, it seems that a long disease free survival interval is usually associated with 
a lower biological aggressivity of the primary tumor, and, therefore, with a better outcome [34].
In a case series of two patients diagnosed with pancreatic metastases from melanomas at 
Melbourne University, Austin Hospital, Victoria, Australia published in 2003, the authors reported 
encouraging results; the first case was the one of a 45-year-old woman with personal history of 
ocular melanoma treated by transscleral resection 12 years earlier, the histopathological studies 
revealing at that moment a 10 mm mixed spindle and epithelioid cell melanoma; however, she 
experienced an early local recurrence 1 year postoperatively, laser therapy being performed at 
the time of relapse. About 11 years later (after the first local relapse), the patient was diagnosed 
with a pancreatic head tumor in association with three to four well defined hepatic nodules mea-
suring 5–10 mm, while the fine needle biopsy confirmed the metastatic character of the tumor 
originating from the melanoma. The patient was submitted to a pylorus preserving pancreato-
duodenectomy and segmental liver resection, the histopathological studies confirming the meta-
static character of all the resected tumors. The patient was free of disease at 6 months follow-up. 
The second reported case from the same authors was the one of a 55-year-old patient known 
with a previous history of ocular melanoma enucleated 13 years earlier who complained of epi-
gastric pain and was diagnosed with a tumoral mass at the level of the pancreatic head; intra-
operatively multiple pigmented lesions were seen on the whole surface of the pancreas, so the 
patient was submitted to total pancreatectomy and remained free of disease 7 months later [34].
Wood’s series conducted on a group of six patients with pancreatic metastases forming mela-
nomas, complete surgical resection of the pancreatic lesion was associated with a median 
overall survival rate of 24 months, significantly higher than the survival rates after palliative 
chemotherapy (where the median overall survival rate does not surpass 12 months) [35, 36]. 
However, in Woods’ study one of the most important prognostic factors was related to the 
resection margins, patients presenting with positive resection margins or incomplete resec-
tion being associated with a significantly poorer outcome (in fact in these cases the median 
survival rate was 8 months, similar to the one reported after palliative chemotherapy) [35]. In 
conclusion incomplete resection has no benefit in terms of survival.
7. Pancreatic metastases from breast cancer
Intra-abdominal breast cancer metastases are usually diagnosed at the level of the liver, 
spleen or axial skeleton [37]. When reported, pancreatic metastases from breast cancer are 
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usually associated with other disseminated lesions. Oligometastatic disease has been rarely 
diagnosed; however, these kinds of lesions might be seen after a long disease free survival 
interval; therefore, the diagnostic of metastatic disease should be kept in mind whenever a 
pancreatic tumor is diagnosed in a patient with previous history of breast cancer [38, 39]. In 
such cases, the clinical signs and symptoms can range from totally asymptomatic lesions to 
diffuse upper abdominal pain, jaundice or acute pancreatitis due to the concomitant obstruc-
tion of the common bile duct or of the Wirsung duct [38, 39].
Pancreatic metastases from breast cancer have been reported with an incidence of 13% in 
autopsy studies and are usually associated with other disseminated lesions, transforming the 
patient into a candidate for a palliative oncologic treatment [40]. However, in cases present-
ing as oligometastatic lesions, surgery has been proposed, this therapeutic approach being 
encouraged by the success reported by hepatobiliary surgeons who performed surgery for 
isolated hepatic metastatic with mammary origin [41].
Bednar et al. reported a case series of two patients diagnosed with pancreatic metastases from 
breast cancer origin. The first one was the case of a 75-year-old patient diagnosed with an inva-
sive lobular breast carcinoma at 58 years of age for which she was submitted to a radical mas-
tectomy at that moment, followed by adjuvant hormonal therapy based on tamoxifen. About 
18 years later, the patient was investigated for weight loss, jaundice and she was diagnosed 
with a pancreatic head tumor; she was resubmitted to surgery, a pancreatoduodenectomy 
being performed. The histopathological studies confirmed the presence of a metastatic lesion 
originating from the primary breast cancer; postoperatively, she was resubmitted to hormonal 
treatment. At 4 year follow-up, the patient was alive with disease, disseminated metastatic 
lesions in the contralateral axilla being found. The second case was the one of a 57-year-old 
patient initially diagnosed with stage IIA mixed cellularity Hodgkin’s lymphoma initially 
treated by radiotherapy, which developed 19 years after breast tumor. At that moment the 
patient was submitted to surgery, the histopathological studies demonstrating the presence of 
a high grade phyllodes tumor. About 4 years later, the patient was diagnosed with a pancre-
atic head tumor, in association with lung nodules which were biopsied, the histopathological 
studies confirming the metastatic character originating from the phyllodes tumor. Therefore 
the patient was submitted to palliative chemotherapy and died 15 months later [42].
8. Pancreatic metastases from ovarian cancer
Ovarian cancer remains one of the most aggressive gynecological malignancies due to the 
fact that most often patients are diagnosed in advanced stages of disease, when dissemi-
nated lesions are already present. In such cases, the principles of debulking surgery were 
successfully applied especially for pelvic confined disease. However, patients presenting 
extended upper abdominal lesions were considered to a have a poorer outcome due to a 
more aggressive surgical biology. This myth was destroyed by the first studies which incor-
porated extended upper abdominal resections as part of debulking surgery; in Eisenhauer’s 
study conducted between 1998 and 2003, 262 patients with advanced stage ovarian cancer 
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were included. These patients were divided in 3 groups according to the time when the 
surgical procedure was performed: there were 57 patients submitted to surgery after the 
date of May 2000 when extensive upper abdominal resections were performed as part of 
debulking surgery. Groups 2 and 3 were submitted to surgery before that date and included 
122 patients submitted to cytoreductive surgery for pelvic confined disease (group 2) and 83 
patients, respectively, submitted to debulking surgery for extensive lesions (group 3); there-
fore, most patients in the third group were suboptimally cytoreduced due to the extension of 
the tumoral process in the upper abdomen. The authors demonstrated a median progression 
free survival of 24, 23 and 11 months, respectively, for groups 1, 2 and 3. Moreover the author 
reported a median overall survival of 84 months for group number 2, 28 months for group 
number 3 and was not reached by the end of the study for group number 1. In conclusion, 
the authors underlined that the long-term outcomes were not influenced by the extension of 
the upper abdominal resections as part of debulking surgery, the only factor which strongly 
shortened survival being the presence of residual disease [43]. Therefore the upper abdomi-
nal resections were successfully included as part of debulking surgery for both advanced 
and recurrent ovarian cancer.
Pancreatic metastases from ovarian cancer usually develop as part of systemic dissemination 
of the malignant process, the main patterns of spread including peritoneal, hematogenous or 
lymphatic spread. When it comes to the pancreatic involvement due to ovarian cancer, the 
most commonly involved mechanisms include peritoneal and hematogenous spread.
When it comes to the association of pancreatic surgery as part of debulking surgery for 
advanced stage or relapsed ovarian cancer, it has been initially considered that association of 
such procedures will lead to the apparition of an unacceptable risk of perioperative compli-
cations. However, a study conducted by Kehoe et al. demonstrated that these surgical pro-
cedures can be successfully associated as part of debulking surgery. The authors reported 
a series of 17 patients submitted to distal pancreatectomies for pancreatic metastases with 
ovarian origin, the median age of patients being of 63 years. When it comes to the surgical out-
comes, nine patients were submitted to debulking surgery to no residual disease, seven cases 
were submitted to optimal cytoreductive surgery while in one case a suboptimal cytoreduc-
tive surgery was performed; however, in this last case the presence of tumoral residual lesions 
was described at the level of the diaphragm and in the liver. When it comes to the short-term 
outcomes, the authors reported a morbidity rate of 24%, all patients being diagnosed with 
pancreatic fistulas. However, the presence of pancreatic fistulas did not impede the adminis-
tration of the adjuvant therapy. Moreover, the rate of pancreatic leaks was similar to the one 
reported by surgeons performing pancreatic resections for pancreatic primaries, demonstrat-
ing in this way that pancreatic surgery can be safely associated as part of debulking surgery 
for advanced stage or recurrent ovarian cancer [44].
When it comes to the long-term outcomes after pancreatic resections for advanced stage or 
recurrent ovarian cancer, an interesting study was conducted in Fundeni Clinical Hospital, 
Bucharest, Romania, and was conducted by Bacalbasa et al. The study included one patient 
submitted to pancreatic resections as part of primary cytoreduction, four cases submitted to 
surgery as part of secondary cytoreduction and one case submitted to pancreatic resection 
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as part of tertiary cytoreduction. The patient submitted to primary cytoreduction benefitted 
from a distal pancreatectomy in association with splenectomy which was associated to a total 
hysterectomy with bilateral adnexectomy, pelvic and para-aortic lymph node dissection and 
parcelar gastrectomy; the long-term outcome was a favorable one, the patient being diag-
nosed with relapse at 54 months follow-up. Patients submitted to pancreatic resections as 
part of secondary cytoreduction experienced a median disease free interval of 32 months and 
necessitated in all cases a distal pancreatectomy. Postoperatively, two patients developed 
pancreatic leaks which were treated conservatively in one case and through reoperation in 
the second case. When it comes to the long-term outcomes, the median overall survival was 
36.38 months, all cases being dead of disease at the end of the study. At the time of tertiary 
cytoreduction, pancreatic resection was performed in a single case, 52 months after the ini-
tial diagnostic. Although the early postoperative outcome was favorable, the patient died of 
disease 10 months later. The authors demonstrated in this way the effectiveness of pancreatic 
resections as part of cytoreductive surgery in the setting of advanced stage disease as well as 
for patients diagnosed with recurrent lesions [45].
Name, year of 
the study
Period of 
the study
No. of patients Type of 
pancreatic 
resection
Early 
postoperative 
outcomes
Long-term outcomes
Chi, 2004 [47] 2001–2002 70 cases, 3 patients 
necessitating 
pancreatic resections
DP: 3 cases 0 Not reached at the end of 
the study (for the entire 
group)
Eisenhauer, 2000 
[43]
2000–2003 57 cases, 6 patients 
necessitating 
pancreatic resections
DP: 6 cases NR Not reached at 36 months 
follow-up (for the entire 
group)
Chi, 2006 [48] 1989–2003 465 cases, 2 patients 
necessitating 
pancreatic resections
DP: 2 cases 0.6% 106 months—in cases 
submitted to complete 
cytoreductive surgery
Chi, 2009 [49] 2001–2004 210 cases, 9 patients 
necessitating 
pancreatic resections
DP: 9 cases 1% Overall survival after 
pancreatic resections: 54 
months
Hoffman, 2007 
[50]
2002–2004 6 cases, 2 patients 
necessitating 
pancreatic resections
DP: 2 cases 0 Overall survival after 
pancreatic resections: not 
reported
Chi, 2010 [51] 2001–2006 141 cases, 17 patients 
necessitating 
pancreatic resections
DP: 17 cases 1.4% Overall survival after 
pancreatic resections: 57 
months
Rodriguez, 2013 
[52]
2001–2004 482 cases, 12 patients 
necessitating 
pancreatic resections
DP: 12 cases Not reported Overall survival after 
pancreatic resections: 54.6 
months
Heitz, 2016 [53] 2005–2010 578 cases, 13 patients 
necessitating 
pancreatic resections
DP: 13 cases 2% Overall survival after 
pancreatic resections: 49 
months
Abbreviations: DP, distal pancreatectomy.
Table 2. Outcomes after pancreatic resections for pancreatic metastases from ovarian carcinomas.
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An interesting such case was reported by Rania Abadeer in 2010 and referred at a 43-year-old 
patient who was initially submitted to surgery for an adult granulosa cell tumor for which a 
salpingo-oophorectomy was performed. About 7 years later, the patient was diagnosed with 
disseminated lesions infiltrating the pelvic wall, so she was resubmitted to surgery, a total hys-
terectomy with left adnexectomy and bilateral pelvic lymph node dissection being performed; 
at that moment debulking surgery to no residual disease was achieved, the histopathologi-
cal findings confirming the metastatic origin from the adult cell granulosa tumor; therefore 
the patient was submitted to adjuvant taxol and platinum-based chemotherapy. However, 
3 years later, the patient was diagnosed with a 4.2 × 4.1 cm pancreatic cyst located at the 
cephalic level so a fine needle aspiration was performed, the cystic fluid presenting no signs 
of malignant cells. Due to the fact that the cyst continued experiencing a fast growth process, 
the patient was submitted to surgery, the frozen section of the cystic wall being suggestive for 
malignancy; due to this aspect, the surgical procedure was completed by performing a pan-
creatoduodenectomy. The immunohistochemical studies confirmed the metastatic origin of 
the lesion originating from the initial adult granulosa cell tumor. The long-term outcome was 
favorable, at 30 months follow-up the patient being free of any recurrent disease [46].
The outcomes after pancreatic resection for pancreatic metastases with ovarian cancer origin 
are shown in Table 2.
9. Pancreatic metastases from uterine body or cervix cancer
Pancreatic metastases from uterine primaries are other rare eventualities, only few cases being 
described so far [1, 54–56]. The main pattern of spread responsible for the apparition of pancre-
atic metastases with endometrial origin consists of hematogenous disseminations and it is usu-
ally responsible for the apparition of other distant lesions such as hepatic, pulmonary or splenic 
metastases [57]. Due to this aspect, pancreatic metastases from uterine carcinomas can be rarely 
treated with curative intent. The first authors who reported performing a surgical procedure 
for a pancreatic metastasis originating from an endometrial carcinoma came from the USA, in 
1998; it was the case of a patient known with previous history of endometrial cancer who pre-
sented for upper digestive stenosis 3 years later. At this time, a 4 cm tumor located at the level 
of the uncinate process of the pancreas was found, so the patient was successfully submitted to 
surgery; unfortunately the authors did not report the performed surgical procedure or the out-
come of this patient [2]. The first successful pancreatic resection for pancreatic metastases from 
endometrial cancer came from Dan Blazer, at M.D. Cancer Center, Houston, Texas, United States 
of America, in 2008. It was the case of a 56-year-old patient who had been previously submitted 
to surgery for endometrial cancer, at that moment a total hysterectomy with bilateral adnex-
ectomy, pelvic and para-aortic lymph node dissection being performed; postoperatively, the 
patient was submitted to adjuvant radiotherapy. However, 31 months later, she was diagnosed 
with a pancreatic lesion measuring 3 × 3 cm in the pancreatic tail. The fine needle biopsy con-
firmed the metastatic origin, so the patient was resubmitted to surgery, a distal pancreatectomy 
being performed. The histopathological studies confirmed the metastatic origin of the lesion; 
however, 6 months later, the patient remained free of recurrent disease [55].
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Pancreatic oligometastases with uterine cervix origin is another rare situation, a successful 
resection of such a lesion being reported for the first time by Wastell et al. in Westminster, 
London. The authors reported the case of a patient who had been initially treated by radio-
therapy with curative intent for a squamous cell carcinoma; however, 5 years later, the patient 
was diagnosed with a pancreatic head tumor. At that moment a pancreatoduodenectomy 
was performed, the histopathological studies confirming the metastatic origin of this lesion; 
unfortunately the postoperative course was complicated by the apparition of a bronchopneu-
monia, the patient being dead 16 days later [58].
Another interesting case was reported by the Japanese authors in 2013 [59]. The authors 
reported the case of a 44-year-old patient who had been initially diagnosed with a stage IB 
uterine cervix cancer, the histopathological studies reporting a mixed adeno-neuroendocrine 
carcinoma; 8 years later, the patient was diagnosed with an isolated pancreatic tumor which 
was biopsied, a metastatic neuroendocrine tumor being revealed. At that moment a central 
pancreatectomy was performed, the histopathological studies confirming the presence of a 
metastatic lesion; however, only the neuroendocrine component seems to be responsible for 
the apparition of the recurrent disease. The long-term outcomes were favorable, the patient 
being free of disease at a 7 month follow-up [59].
10. Pancreatic metastases from lung cancer
Lung cancer is associated with the highest mortality rates, being associated most often with 
liver, brain, bone or lymph node metastases [60].
Pancreatic metastases from lung cancer are not a usual condition; in a review of 333 cases 
diagnosed with pancreatic metastases, the most common origin of the pancreatic lesions 
was represented by the renal cell carcinomas, being responsive for 45% of cases; among the 
remaining cases, the lung was reported as the origin of the pancreatic metastases in 14.7% 
of cases [61].
When it comes to the most common histopathological subtype of lung cancer which might 
induce the apparition of pancreatic lesions, small cell lung cancer has been most often 
reported; other incriminated histopathological subtypes included large cell carcinomas, squa-
mous cell carcinomas and anaplastic bronchial carcinomas [62].
When diagnosed, pancreatic metastases from lung cancer are usually encountered as 
part of the systemic recurrence, with metachronous character; therefore the patient will 
be a candidate for palliative oncologic treatment, with low rates of long-term survival. 
Oligometastatic pancreatic disease with lung cancer origin appears in rare situations 
and it seem to be best treated through surgery with curative intent; however, the long-
term outcomes failed to demonstrate good survival rates, the median overall survival 
ranging from a few months to a few years [10] due to biological aggressiveness of the 
primary tumor.
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11. Pancreatic cancer from sarcomas
Metastatic lesions with sarcomatous origin are usually associated with an extremely poor out-
come due to the biological aggressiveness of such primaries. When encountered, pancreatic 
metastases with sarcomatous origin are reported as part of the systemic disease so most often 
surgery is no longer a valid therapeutic option. In cases presenting oligometastatic disease, 
surgery might be proposed whenever the biological status of the patient will permit it. A par-
ticular problem in such cases is related to the multifocality of such lesions and to the feasibil-
ity of resection with curative intent [7].
Successful resection of pancreatic metastases from soft tissue sarcomas has been reported by 
the Japanese authors in two cases. The first patient had been initially diagnosed with a mes-
enchymal chondrosarcoma of the left thigh in 1986; 3 years later, the patient was diagnosed 
with isolated pancreatic lesions, the patient being submitted to surgery with curative intent; 
the patient remained alive for the next 10 years. The second case was initially diagnosed with 
a synovial sarcoma followed by pulmonary resection for metastatic disease; the case was fur-
ther diagnosed with a solitary pancreatic lesion for which she was submitted to pylorus pre-
serving pancreatoduodenectomy with good results, the patient remaining alive for more than 
6 years after pancreatic resection [63].
Another extremely interesting situation was reported by another Japanese team in 2016. The 
authors reported the case of a 44-year-old woman who had been previously submitted to 
surgery for a right fibular head osteosarcoma; 3 years later, the patient was diagnosed with 
a metastasis in the distal pancreas, so a laparoscopic distal pancreatectomy with spleen pres-
ervation was successfully performed; the histopathological studies confirmed the metastatic 
origin from the initial osteosarcoma. Although the patient also reported the apparition of lung 
metastases, 1 year later, she was resubmitted to surgery with curative intent, the patient being 
still alive at the time of publishing the case [64].
A particular situation is represented by patients diagnosed with pancreatic metastases from 
uterine sarcomas, in cases presenting oligometastatic disease, surgery being considered as a 
valid option. Most often these lesions occur in patients who had been previously diagnosed 
with uterine leiomiosarcomas and might experience good long-term outcomes whenever a 
curative resection is performed [65, 66].
12. Conclusion
Isolated pancreatic metastases suitable for resection are rare eventualities; the renal cell carci-
noma origin being the most frequently reported situations. When diagnosed as metachronous 
isolated lesions, such metastases can be submitted to surgery with curative intent, long-term 
survival rates being reported. Another primary with good outcomes after pancreatic resections 
for metastatic disease is represented by ovarian cancer, debulking surgery to no residual disease 
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including pancreatic resections being associated with long-term survival. When it comes to the 
other origins, the reported results are inconstant and no standard therapeutic protocol can be 
established due to the paucity of cases. However, it seems that the best outcomes should be 
expected in cases diagnosed with isolated metachronous lesions with long disease free survival 
intervals and in the absence of extrapancreatic disease. In such cases, association of surgery as 
part of multidisciplinary approach might improve the long-term outcomes.
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